Invitation - Presentation of Moberg Pharma's fourth quarter and full year results 2014

STOCKHOLM, February 18, 2015 -- On February 27, at 08:00 CET, Moberg Pharma AB
(OMX: MOB) will publish its report for the fourth quarter and full year 2014
(note: changed date).
Financial analysts and media are invited to participate in a telephone
conference, which will include a presentation of the results, Monday, March 2nd
at 14:00 CET. The event will be hosted by Peter Wolpert, CEO of Moberg Pharma
AB, and the presentation will be held in English.

Slides used in the presentation will be made available on our website prior to
the telephone conference.

To participate in the telephone conference, please call:

SE: +46 8 56642700
US: +1 8558315945

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 08:30 am (CET) on February 18, 2015.
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
a direct sales and marketing organization in the U.S. and an extensive
distributor network in more than 40 countries. The company’s portfolio includes
the OTC brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and
Fergon®as well as Phase II pipeline assets. Kerasal Nail®(Emtrix®and Nalox™in
certain markets outside the U.S.) is the leading product for the treatment of
nail disorders in the U.S. and Nordic market. The current portfolio will be
supplemented by the acquisition and in-licensing of additional products as well
as product development with a focus on innovative drug delivery of proven
compounds. Moberg Pharma has offices in Stockholm and New Jersey and the
company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX
Nordic Exchange Stockholm. For further information, please visit:
www.mobergpharma.com.